2007
DOI: 10.1002/lt.21146
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil

Abstract: The bioavailability of mycophenolic acid (MPA) after oral administration of mycophenolate mofetil (MMF) has been reported to be more than 90% in healthy volunteers, and in kidney and thoracic organ transplant patients. Such information is limited in liver transplant (LTx) patients. The present study compares the pharmacokinetics of MPA after intravenous (IV) and oral administrations of MMF in LTx recipients. Pharmacokinetic parameters were calculated using WinNonlin software. A total of 12 deceased donor LTx p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
23
0

Year Published

2008
2008
2014
2014

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 32 publications
(26 citation statements)
references
References 44 publications
3
23
0
Order By: Relevance
“…In healthy patients, bioavailability after single-dose oral administration of 1.5 g of MMF was 85.7% for the MPA AUC 0 -24 and 93.3% for the MPA AUC 0 -ϱ in comparison with the intravenous formulation (25). However, MMF bioavailability seems to be decreased to 48.5% in liver transplant patients treated with 1 g of oral MMF two times daily (26). Also, in hematopoietic stem cell transplant recipients treated with 1 g of MMF in combination with cyclosporine, a decreased and highly variable bioavailability was seen (F ϭ 72.3%, range 20.5% to 172%) (27).…”
Section: Discussionmentioning
confidence: 90%
“…In healthy patients, bioavailability after single-dose oral administration of 1.5 g of MMF was 85.7% for the MPA AUC 0 -24 and 93.3% for the MPA AUC 0 -ϱ in comparison with the intravenous formulation (25). However, MMF bioavailability seems to be decreased to 48.5% in liver transplant patients treated with 1 g of oral MMF two times daily (26). Also, in hematopoietic stem cell transplant recipients treated with 1 g of MMF in combination with cyclosporine, a decreased and highly variable bioavailability was seen (F ϭ 72.3%, range 20.5% to 172%) (27).…”
Section: Discussionmentioning
confidence: 90%
“…Clinical practice suggests that a target Ն1 mg/L is important in the first year after transplantation to minimize rejection, whereas levels should be kept below approximately 3.5 mg/L subsequently to reduce the incidence of adverse effects. Initial intravenous MMF dosing can be considered in liver (and possibly bowel) transplantation to compensate for decreased drug bioavailability early after grafting (12).…”
Section: Liver Bowel and Pancreas Transplantationmentioning
confidence: 99%
“…Large interindividual variation in MPA pharmacokinetics after oral administration has been well‐recognized in liver transplant recipients 9, 11, 17. In this study, such a phenomenon still remained not only in DDLT patients but also in LDLT patients.…”
Section: Discussionmentioning
confidence: 64%